Amgen (NASDAQ:AMGN) Price Target Raised to $350.00

Amgen (NASDAQ:AMGN) had its price target hoisted by Cantor Fitzgerald from $315.00 to $350.00 in a research report sent to investors on Wednesday, Marketbeat Ratings reports. The brokerage currently has a neutral rating on the medical research company’s stock.

A number of other research analysts have also recently weighed in on AMGN. Piper Sandler boosted their target price on shares of Amgen from $342.00 to $381.00 and gave the company an “overweight” rating in a research note on Friday, November 14th. UBS Group lifted their price target on shares of Amgen from $380.00 to $390.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Daiwa Securities Group increased their price objective on Amgen from $310.00 to $370.00 and gave the company an “outperform” rating in a report on Tuesday, November 18th. Scotiabank initiated coverage on Amgen in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $385.00 target price for the company. Finally, HSBC restated a “buy” rating and issued a $425.00 target price on shares of Amgen in a research note on Wednesday, December 10th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $351.65.

Amgen Stock Performance

Shares of Amgen stock opened at $384.20 on Wednesday. The business’s fifty day simple moving average is $334.45 and its 200 day simple moving average is $311.45. The firm has a market capitalization of $206.88 billion, a P/E ratio of 27.00, a price-to-earnings-growth ratio of 3.73 and a beta of 0.46. Amgen has a 12 month low of $261.43 and a 12 month high of $385.12. The company has a current ratio of 1.14, a quick ratio of 0.99 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The firm had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, analysts anticipate that Amgen will post 20.62 EPS for the current year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Amgen’s previous quarterly dividend of $2.38. Amgen’s payout ratio is 66.90%.

Insider Activity

In other Amgen news, SVP Rachna Khosla sold 890 shares of Amgen stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the sale, the senior vice president directly owned 7,082 shares in the company, valued at $2,381,251.68. The trade was a 11.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Murdo Gordon sold 6,879 shares of the stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the completion of the transaction, the executive vice president directly owned 41,923 shares in the company, valued at $14,120,924.09. The trade was a 14.10% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 10,908 shares of company stock worth $3,674,966. 0.76% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Anfield Capital Management LLC lifted its stake in Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after purchasing an additional 70 shares during the last quarter. Dogwood Wealth Management LLC raised its holdings in shares of Amgen by 275.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after buying an additional 55 shares in the last quarter. Board of the Pension Protection Fund bought a new stake in Amgen in the 4th quarter worth approximately $26,000. Legacy Investment Solutions LLC purchased a new stake in Amgen in the second quarter worth approximately $27,000. Finally, Evelyn Partners Investment Management LLP bought a new position in Amgen during the second quarter valued at approximately $32,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Argus raised its price target to $400 and reiterated a Buy rating, signaling analyst confidence in Amgen’s outlook and providing fresh positive momentum for the stock. Read More.
• Positive Sentiment: Q4 results beat Street estimates and management’s commentary pushed the shares to a new 12‑month high — the earnings beat and upgraded FY‑2026 guidance underpin the rally. Read More.
• Positive Sentiment: Clinical progress: Amgen advanced xaluritamig into a first‑in‑human Phase 1b trial for hard‑to‑treat Ewing sarcoma — a development that adds long‑term pipeline upside if the program shows activity. Read More.
• Positive Sentiment: Post‑marketing safety study for IMLYGIC in melanoma reached completion — reduces an uncertainty from the label/safety perspective and may support that asset’s commercial outlook. Read More.
• Neutral Sentiment: Guggenheim raised its price target to $347 but kept a Neutral rating; the new PT still implies downside versus the current price, creating mixed signals for investors. Read More.
• Neutral Sentiment: Deutsche Bank moved its target to $295 and maintained a Hold — another measured call that tempers the enthusiasm from Buy-rated upgrades. Read More.
• Neutral Sentiment: Market commentary notes rotation into defensive/health names and institutional buying as contributors to the stock’s move to multi‑month highs — a broader-market technical tailwind rather than company‑specific news. Read More.
• Negative Sentiment: CVS said it will replace Amgen’s and Lilly’s bone‑disease treatments with lower‑cost alternatives on some preferred drug lists starting April 1 — a material commercial headwind for the affected product sales. Read More.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.